Once we understand if the Sst-mediated slowing of Aβ aggregation reduces or exacerbates toxicity in vivo, refined strategies should come to the fore that can harness the still untapped therapeutic potential of this cyclic neuropeptide for the treatment of AD. The gene discussed is SST; the disease is Alzheimer disease.